Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies
연구 개요
상세 설명
This was a Phase 1/2, multi-center, open-label study comprising a Phase 1 dose escalation part followed by a Phase 2 dose expansion part.
During the Phase 1 dose escalation part patients with any advanced solid tumor received the study treatment until the MTD was reached or a lower RP2D was established. The study had the following 3 dose escalation parts: 1) Single-agent LAG525; 2) Single-agent LAG525 in Japanese patients; 3) Combination of LAG525 with PDR001.
Once the RP2D or MTD had been determined in the escalation parts, additional patients were to be enrolled in the Phase 2 expansion parts in order to assess the preliminary anti-tumor activity. Phase 2 expansion cohorts testing single-agent LAG525 were not opened for enrollment based on emerging data including but not limited to preliminary anti-tumor activity. Phase 2 expansion cohorts for the combination of LAG525 with PDR001 were opened and 5 tumor types were assessed: 1) Non-small cell lung cancer (NSCLC); 2) Melanoma; 3) Renal cell cancer (RCC); 4) Mesothelioma; 5) Triple negative breast cancer (TNBC). The efficacy and safety of the combination of LAG525 with PDR001 in these tumor types was assessed in both the PD-1/PD-L1 pre-treated and naïve settings.
연구 유형
등록 (실제)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 장소
-
-
-
Taipei, 대만, 10002
- Novartis Investigative Site
-
-
-
-
-
Heidelberg, 독일, 69120
- Novartis Investigative Site
-
Wuerzburg, 독일, 97080
- Novartis Investigative Site
-
-
-
-
New York
-
New York, New York, 미국, 10032
- Columbia University Medical Center SC LAG X2101C
-
New York, New York, 미국, 10065
- Memorial Sloan Kettering Cancer Center SC
-
-
North Carolina
-
Durham, North Carolina, 미국, 27704
- Duke Clinical Research Institute SC
-
-
Texas
-
Houston, Texas, 미국, 77030
- University of Texas MD Anderson Cancer Center
-
San Antonio, Texas, 미국, 78229
- Cancer Therapy and Research Center UT Health Science Center CTRC 2
-
-
Utah
-
Salt Lake City, Utah, 미국, 84112
- Huntsman Cancer Institute Huntsman Cancer Institute
-
-
-
-
-
Leuven, 벨기에, 3000
- Novartis Investigative Site
-
-
-
-
-
Madrid, 스페인, 28009
- Novartis Investigative Site
-
-
Catalunya
-
Barcelona, Catalunya, 스페인, 08035
- Novartis Investigative Site
-
-
-
-
-
Singapore, 싱가포르, 119228
- Novartis Investigative Site
-
Singapore, 싱가포르, 169610
- Novartis Investigative Site
-
-
-
-
MI
-
Milano, MI, 이탈리아, 20133
- Novartis Investigative Site
-
-
MO
-
Modena, MO, 이탈리아, 41124
- Novartis Investigative Site
-
-
-
-
Fukuoka
-
Fukuoka-city, Fukuoka, 일본, 811-1395
- Novartis Investigative Site
-
-
-
-
Alberta
-
Edmonton, Alberta, 캐나다, T6G 1Z2
- Novartis Investigative Site
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5G 2M9
- Novartis Investigative Site
-
-
-
-
-
Lyon Cedex, 프랑스, 69373
- Novartis Investigative Site
-
Saint-Herblain Cédex, 프랑스, 44805
- Novartis Investigative Site
-
-
-
-
New South Wales
-
Westmead, New South Wales, 호주, 2145
- Novartis Investigative Site
-
-
Victoria
-
Heidelberg, Victoria, 호주, 3084
- Novartis Investigative Site
-
-
-
-
-
Hong Kong, 홍콩
- Novartis Investigative Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Phase I part:
- Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease as determined by RECIST version 1.1, who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists
Phase II part:
- Patients with advanced/metastatic solid tumors, with at least one measurable lesion as determined by RECIST version 1.1, who have had disease progression following their last prior therapy and fit into one of the following groups:
- Group 1: NSCLC
- Group 2: Melanoma
- Group 3: Renal cancer
- Group 4: Mesothelioma
- Group 5: TNBC
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1
- Patient must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy.
Exclusion Criteria:
- History of severe hypersensitivity reactions to study treatment ingredients or other mAbs
- Active, known or suspected autoimmune disease
- Active infection requiring systemic antibiotic therapy
- HIV infection. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
- Patients receiving chronic treatment with systemic steroid therapy, other than replacement-dose corticosteroids in the setting of adrenal insufficiency
- Patients receiving systemic treatment with any immunosuppressive medication
- Use of live vaccines against infectious disease within 4 weeks of initiation of study treatment
- Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment.
- Presence of symptomatic central nervous system (CNS) metastases or CNS metastases that require local CNS-directed therapy or increasing doses of corticosteroids within the prior 2 weeks
- History of drug-induced pneumonitis or current pneumonitis.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Phase 1: LAG525 1 mg/kg Q2W
Single-agent LAG525 1 mg/kg Q2W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
실험적: Phase 1: LAG525 3 mg/kg Q2W
Single-agent LAG525 3 mg/kg Q2W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
실험적: Phase 1: LAG525 5 mg/kg Q2W
Single-agent LAG525 5 mg/kg Q2W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
실험적: Phase 1: LAG525 10 mg/kg Q2W
Single-agent LAG525 10 mg/kg Q2W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
실험적: Phase 1: LAG525 15 mg/kg Q2W
Single-agent LAG525 15 mg/kg Q2W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
실험적: Phase 1: LAG525 240 mg Q2W
Single-agent LAG525 240 mg Q2W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
실험적: Phase 1: LAG525 400 mg Q2W
Single-agent LAG525 400 mg Q2W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
실험적: Phase 1: LAG525 3 mg/kg Q4W
Single-agent LAG525 3 mg/kg Q4W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
실험적: Phase 1: LAG525 5 mg/kg Q4W
Single-agent LAG525 5 mg/kg Q4W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
실험적: Phase 1: LAG525 10 mg/kg Q4W
Single-agent LAG525 10 mg/kg Q4W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
실험적: Phase 1: LAG525 400 mg Q4W
Single-agent LAG525 400 mg Q4W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
실험적: Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W
Combination LAG525 0.3 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
실험적: Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W
Combination LAG525 1 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
실험적: Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W
Combination LAG525 80 mg + PDR001 80 mg (Q2W/Q2W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
실험적: Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W
Combination LAG525 80 mg + PDR001 240 mg (Q2W/Q2W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
실험적: Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W
Combination LAG525 240 mg + PDR001 240 mg (Q2W/Q2W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
실험적: Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W
Combination LAG525 240 mg + PDR001 300 mg (Q3W/Q3W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
실험적: Phase 1: LAG525 400 mg Q3W + PDR001 300 mg Q3W
Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
실험적: Phase 1: LAG525 600 mg Q3W + PDR001 300 mg Q3W
Combination LAG525 600 mg + PDR001 300 mg (Q3W/Q3W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
실험적: Phase 1: LAG525 80 mg Q4W + PDR001 240 mg Q4W
Combination LAG525 80 mg + PDR001 240 mg (Q4W/Q4W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
실험적: Phase 1: LAG525 400 mg Q4W + PDR001 400 mg Q4W
Combination LAG525 400 mg + PDR001 400 mg (Q4W/Q4W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
실험적: Phase 1: LAG525 800 mg Q4W + PDR001 400 mg Q4W
Combination LAG525 800 mg + PDR001 400 mg (Q4W/Q4W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
실험적: Phase 1: LAG525 1000 mg Q4W + PDR001 400 mg Q4W
Combination LAG525 1000 mg + PDR001 400 mg (Q4W/Q4W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
실험적: Phase 1: LAG525 80 mg Q2W + PDR001 400 mg Q4W
Combination LAG525 80 mg + PDR001 400 mg (Q2W/Q4W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
실험적: Phase 1: LAG525 240 mg Q2W + PDR001 400 mg Q4W
Combination LAG525 240 mg + PDR001 400 mg (Q2W/Q4W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
실험적: Phase 1: LAG525 300 mg Q2W + PDR001 400 mg Q4W
Combination LAG525 300 mg + PDR001 400 mg (Q2W/Q4W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
실험적: Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W
Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
실험적: Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W
Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
실험적: Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W
Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)
기간: 15 days for single-agent LAG525 arms and 30 days for the combination LAG525 + PDR001 arms
|
A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle of treatment with single-agent LAG525 or within the first two cycles of treatment with the combination of LAG525 and PDR001.
Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.
|
15 days for single-agent LAG525 arms and 30 days for the combination LAG525 + PDR001 arms
|
|
Phase 2: Overall Response Rate (ORR) Per RECIST 1.1
기간: From start of treatment until end of treatment, assessed up to 2.6 years
|
Tumor response was based on local investigator assessment and the assessment criteria was Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). ORR per RECIST 1.1 is defined as the percentage of participants with a best overall response of Complete Response (CR) or Partial Response (PR). For RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters. ORR is reported by tumor type. |
From start of treatment until end of treatment, assessed up to 2.6 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Phase 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
기간: From first dose of study treatment until last dose of study treatment plus 30 days post treatment, assessed up to 4.5 years.
|
Number of participants with AEs and SAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs.
The number of participants in each category (Rest of the World (ROW) patients, Japanese patients) with AEs and SAEs are reported in this record.
|
From first dose of study treatment until last dose of study treatment plus 30 days post treatment, assessed up to 4.5 years.
|
|
Phase 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
기간: From first dose of study treatment until last dose of study treatment plus 30 days post treatment, assessed up to 2.7 years.
|
Number of participants with AEs and SAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs.
The number of participants with AEs and SAEs is reported for each tumor type.
|
From first dose of study treatment until last dose of study treatment plus 30 days post treatment, assessed up to 2.7 years.
|
|
Phase 1: Number of Participants With Dose Reductions and Dose Interruptions of LAG525 and PDR001
기간: From start of treatment until end of treatment, assessed up to 4.4 years.
|
Number of participants with at least one dose reduction of LAG525, at least one dose interruption of LAG525, at least one dose reduction of PDR001 and at least one dose interruption of PDR001. Japanese patients were not treated with PDR001 and therefore the dose reductions and dose interruptions of this study drug are not applicable. |
From start of treatment until end of treatment, assessed up to 4.4 years.
|
|
Phase 2: Number of Participants With Dose Reductions and Dose Interruptions of LAG525 and PDR001
기간: From start of treatment until end of treatment, assessed up to 2.6 years.
|
Number of participants with at least one dose reduction of LAG525, at least one dose interruption of LAG525, at least one dose reduction of PDR001 and at least one dose interruption of PDR001. The number of participants with dose reductions and dose interruptions of both study drugs is reported for each tumor type. |
From start of treatment until end of treatment, assessed up to 2.6 years.
|
|
Phase 1: Relative Dose Intensity (RDI) of LAG525 and PDR001
기간: From start of treatment until end of treatment, assessed up to 4.4 years.
|
Relative dose intensity of each study drug is calculated with the following formula: 100 x actual dose intensity (mg/day)/planned dose intensity (mg/day). Japanese patients were not treated with PDR001 and therefore the RDI of this study drug is not applicable. |
From start of treatment until end of treatment, assessed up to 4.4 years.
|
|
Phase 2: Relative Dose Intensity (RDI) of LAG525 and PDR001
기간: From start of treatment until end of treatment, assessed up to 2.6 years.
|
Relative dose intensity of each study drug is calculated with the following formula: 100 x actual dose intensity (mg/day)/planned dose intensity (mg/day). The RDI of both study drugs is reported for each tumor type. |
From start of treatment until end of treatment, assessed up to 2.6 years.
|
|
Phase 1: Maximum Observed Serum Concentration (Cmax) of LAG525
기간: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods.
Cmax is defined as the maximum (peak) observed serum concentration following a dose.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 2: Maximum Observed Serum Concentration (Cmax) of LAG525
기간: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods.
Cmax is defined as the maximum (peak) observed serum concentration following a dose.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 1: Time to Reach Maximum Serum Concentration (Tmax) of LAG525
기간: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods.
Tmax is defined as the time to reach maximum (peak) serum concentration following a dose.
Actual recorded sampling times were considered for the calculations.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 2: Time to Reach Maximum Serum Concentration (Tmax) of LAG525
기간: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods.
Tmax is defined as the time to reach maximum (peak) serum concentration following a dose.
Actual recorded sampling times were considered for the calculations.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 1: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of LAG525
기간: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods.
The linear trapezoidal method was used for AUC calculation.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 2: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of LAG525
기간: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods.
The linear trapezoidal method was used for AUC calculation.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 1: Terminal Elimination Half-life (T1/2) of LAG525
기간: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods.
Elimination half-life (T1/2) values were calculated as 0.693/terminal elimination rate constant.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 2: Terminal Elimination Half-life (T1/2) of LAG525
기간: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods.
Elimination half-life (T1/2) values were calculated as 0.693/terminal elimination rate constant.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 1: Maximum Observed Serum Concentration (Cmax) of PDR001
기간: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed serum concentration following a dose. Japanese patients were not treated with PDR001 and therefore the PK parameters of this study drug are not applicable. |
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 2: Maximum Observed Serum Concentration (Cmax) of PDR001
기간: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods.
Cmax is defined as the maximum (peak) observed serum concentration following a dose.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 1: Time to Reach Maximum Serum Concentration (Tmax) of PDR001
기간: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) serum concentration following a dose. Actual recorded sampling times were considered for the calculations. Japanese patients were not treated with PDR001 and therefore the PK parameters of this study drug are not applicable. |
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 2: Time to Reach Maximum Serum Concentration (Tmax) of PDR001
기간: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods.
Tmax is defined as the time to reach maximum (peak) serum concentration following a dose.
Actual recorded sampling times were considered for the calculations.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 1: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PDR001
기간: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUC calculation. Japanese patients were not treated with PDR001 and therefore the PK parameters of this study drug are not applicable. |
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 2: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PDR001
기간: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods.
The linear trapezoidal method was used for AUC calculation.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 1: Terminal Elimination Half-life (T1/2) of PDR001
기간: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods. Elimination half-life (T1/2) values were calculated as 0.693/terminal elimination rate constant. Japanese patients were not treated with PDR001 and therefore the PK parameters of this study drug are not applicable. |
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 2: Terminal Elimination Half-life (T1/2) of PDR001
기간: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods.
Elimination half-life (T1/2) values were calculated as 0.693/terminal elimination rate constant.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 1: Number of Participants With Anti-LAG525 Antibodies
기간: Baseline (pre-infusion on Cycle 1 Day 1) and post-baseline (assessed throughout the treatment up to maximum 4.4 years).
|
Validated immunoassays were used for screening and confirmation of the presence of anti-LAG525 antibodies (ADA, anti-drug antibodies) in serum.
Number of participants with ADA in each category is reported in this record.
|
Baseline (pre-infusion on Cycle 1 Day 1) and post-baseline (assessed throughout the treatment up to maximum 4.4 years).
|
|
Phase 2: Number of Participants With Anti-LAG525 Antibodies
기간: Baseline (pre-infusion on Cycle 1 Day 1) and post-baseline (assessed throughout the treatment up to maximum 2.6 years).
|
Validated immunoassays were used for screening and confirmation of the presence of anti-LAG525 antibodies (ADA, anti-drug antibodies) in serum.
Number of participants with ADA in each category is reported in this record.
|
Baseline (pre-infusion on Cycle 1 Day 1) and post-baseline (assessed throughout the treatment up to maximum 2.6 years).
|
|
Phase 1: Number of Participants With Anti-PDR001 Antibodies
기간: Baseline (pre-infusion on Cycle 1 Day 1) and post-baseline (assessed throughout the treatment up to maximum 4.4 years).
|
Validated immunoassays were used for screening and confirmation of the presence of anti-PDR001 antibodies (ADA, anti-drug antibodies) in serum.
Number of participants with ADA in each category is reported in this record.
|
Baseline (pre-infusion on Cycle 1 Day 1) and post-baseline (assessed throughout the treatment up to maximum 4.4 years).
|
|
Phase 2: Number of Participants With Anti-PDR001 Antibodies
기간: Baseline (pre-infusion on Cycle 1 Day 1) and post-baseline (assessed throughout the treatment up to maximum 2.6 years).
|
Validated immunoassays were used for screening and confirmation of the presence of anti-PDR001 antibodies (ADA, anti-drug antibodies) in serum.
Number of participants with ADA in each category is reported in this record.
|
Baseline (pre-infusion on Cycle 1 Day 1) and post-baseline (assessed throughout the treatment up to maximum 2.6 years).
|
|
Phase 1: Overall Response Rate (ORR) Per RECIST 1.1
기간: From start of treatment until end of treatment, assessed up to 4.4 years
|
Tumor response was based on local investigator assessment and the assessment criteria was Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). ORR per RECIST 1.1 is defined as the percentage of participants with a best overall response of Complete Response (CR) or Partial Response (PR). For RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters. ORR is reported for ROW and Japanese patients. |
From start of treatment until end of treatment, assessed up to 4.4 years
|
|
Phase 1: Overall Response Rate (ORR) Per irRC
기간: From start of treatment until end of treatment, assessed up to 4.4 years
|
TTumor response was based on local investigator assessment and the assessment criteria was immune-related Response Criteria (irRC). ORR per irRC is defined as the percentage of participants with a best overall response of immune related Complete Response (irCR) or immune related Partial Response (irPR). For irRC, irCR=Disappearance of all non-nodal target lesions and non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; irPR= At least a 30% decrease in the sum of diameters of all target lesions including new target lesions, taking as reference the baseline sum of diameters. ORR is reported for ROW and Japanese patients. |
From start of treatment until end of treatment, assessed up to 4.4 years
|
|
Phase 2: Overall Response Rate (ORR) Per irRC
기간: From start of treatment until end of treatment, assessed up to 2.6 years
|
Tumor response was based on local investigator assessment and the assessment criteria was immune-related Response Criteria (irRC). ORR per irRC is defined as the percentage of participants with a best overall response of immune related Complete Response (irCR) or immune related Partial Response (irPR). For irRC, irCR=Disappearance of all non-nodal target lesions and non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; irPR= At least a 30% decrease in the sum of diameters of all target lesions including new target lesions, taking as reference the baseline sum of diameters. ORR is reported by tumor type. |
From start of treatment until end of treatment, assessed up to 2.6 years
|
|
Phase 1: Disease Control Rate (DCR) Per RECIST 1.1
기간: From start of treatment until end of treatment, assessed up to 4.4 years
|
Tumor response was based on local investigator assessment and the assessment criteria was Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). DCR per RECIST 1.1 is defined as the percentage of participants with a best overall response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD). For RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters; SD= Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progression. DCR is reported for ROW and Japanese patients. |
From start of treatment until end of treatment, assessed up to 4.4 years
|
|
Phase 1: Disease Control Rate (DCR) Per irRC
기간: From start of treatment until end of treatment, assessed up to 4.4 years
|
Tumor response was based on local investigator assessment and the assessment criteria was immune-related Response Criteria (irRC). DCR per irRC is defined as the percentage of participants with a best overall response of immune related Complete Response (irCR), immune related Partial Response (irPR) or immune related Stable Disease (irSD). For irRC, irCR=Disappearance of all non-nodal target lesions and non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; irPR= At least a 30% decrease in the sum of diameters of all target lesions including new target lesions, taking as reference the baseline sum of diameters; SD= Neither sufficient shrinkage to qualify for irPR or irCR nor an increase in lesions which would qualify for progression. DCR is reported for ROW and Japanese patients. |
From start of treatment until end of treatment, assessed up to 4.4 years
|
|
Phase 2: Disease Control Rate (DCR) Per RECIST 1.1
기간: From start of treatment until end of treatment, assessed up to 2.6 years
|
Tumor response was based on local investigator assessment and the assessment criteria was Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). DCR per RECIST 1.1 is defined as the percentage of participants with a best overall response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD). For RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters; SD= Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progression. DCR is reported by tumor type. |
From start of treatment until end of treatment, assessed up to 2.6 years
|
|
Phase 2: Disease Control Rate (DCR) Per irRC
기간: From start of treatment until end of treatment, assessed up to 2.6 years
|
Tumor response was based on local investigator assessment and the assessment criteria was immune-related Response Criteria (irRC). DCR per irRC is defined as the percentage of participants with a best overall response of immune related Complete Response (irCR), immune related Partial Response (irPR) or immune related Stable Disease (irSD). For irRC, irCR=Disappearance of all non-nodal target lesions and non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; irPR= At least a 30% decrease in the sum of diameters of all target lesions including new target lesions, taking as reference the baseline sum of diameters; SD= Neither sufficient shrinkage to qualify for irPR or irCR nor an increase in lesions which would qualify for progression. DCR is reported by tumor type. |
From start of treatment until end of treatment, assessed up to 2.6 years
|
|
Phase 1: Duration of Response (DOR) Per RECIST 1.1
기간: From first documented response (CR or PR) to first documented progression or death due to study indication, assessed up to 4.4 years
|
DOR only applies to subjects for whom best overall response is complete response (CR) or partial response (PR). DOR is defined as the time from the date of first documented response (CR or PR) to the date of first documented progression or death due to study indication. If a patient not had an event, duration was censored at the date of last adequate tumor assessment. Tumor response was based on local investigator assessment and the assessment criteria was RECIST 1.1. |
From first documented response (CR or PR) to first documented progression or death due to study indication, assessed up to 4.4 years
|
|
Phase 1: Duration of Response (DOR) Per irRC
기간: From first documented response (irCR or irPR) to first documented progression or death due to study indication, assessed up to 4.4 years
|
DOR only applies to subjects for whom best overall response is immune related complete response (irCR) or immune related partial response (irPR). DOR is defined as the time from the date of first documented response (irCR or irPR) to the date of first documented progression or death due to study indication. If a patient not had an event, duration was censored at the date of last adequate tumor assessment. Tumor response was based on local investigator assessment and the assessment criteria was irRC. |
From first documented response (irCR or irPR) to first documented progression or death due to study indication, assessed up to 4.4 years
|
|
Phase 2: Duration of Response (DOR) Per RECIST 1.1
기간: From first documented response (CR or PR) to first documented progression or death due to study indication, assessed up to 2.6 years
|
DOR only applies to subjects for whom best overall response is complete response (CR) or partial response (PR). DOR is defined as the time from the date of first documented response (CR or PR) to the date of first documented progression or death due to study indication. If a patient not had an event, duration was censored at the date of last adequate tumor assessment. Tumor response was based on local investigator assessment and the assessment criteria was RECIST 1.1. DOR is reported by tumor type. |
From first documented response (CR or PR) to first documented progression or death due to study indication, assessed up to 2.6 years
|
|
Phase 2: Duration of Response (DOR) Per irRC
기간: From first documented response (irCR or irPR) to first documented progression or death due to study indication, assessed up to 2.6 years
|
DOR only applies to subjects for whom best overall response is immune related complete response (irCR) or immune related partial response (irPR). DOR is defined as the time from the date of first documented response (irCR or irPR) to the date of first documented progression or death due to study indication. If a patient not had an event, duration was censored at the date of last adequate tumor assessment. Tumor response was based on local investigator assessment and the assessment criteria was irRC. DOR is reported by tumor type. |
From first documented response (irCR or irPR) to first documented progression or death due to study indication, assessed up to 2.6 years
|
|
Phase 1: Progression-free Survival (PFS) Per RECIST 1.1
기간: From start of treatment to first documented progression or death due to any cause, assessed up to 4.4 years
|
PFS is the time from the date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment. Tumor response was based on local investigator assessment and the assessment criteria was RECIST 1.1. PFS is reported for ROW and Japanese patients. |
From start of treatment to first documented progression or death due to any cause, assessed up to 4.4 years
|
|
Phase 1: Progression-free Survival (PFS) Per irRC
기간: From start of treatment to first documented progression or death due to any cause, assessed up to 4.4 years
|
PFS is the time from the date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment. Tumor response was based on local investigator assessment and the assessment criteria was irRC. PFS is reported for ROW and Japanese patients. |
From start of treatment to first documented progression or death due to any cause, assessed up to 4.4 years
|
|
Phase 2: Progression-free Survival (PFS) Per RECIST 1.1
기간: From start of treatment to first documented progression or death due to any cause, assessed up to 2.6 years
|
PFS is the time from the date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment. Tumor response was based on local investigator assessment and the assessment criteria was RECIST 1.1. PFS is reported by tumor type. |
From start of treatment to first documented progression or death due to any cause, assessed up to 2.6 years
|
|
Phase 2: Progression-free Survival (PFS) Per irRC
기간: From start of treatment to first documented progression or death due to any cause, assessed up to 2.6 years
|
PFS is the time from the date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment. Tumor response was based on local investigator assessment and the assessment criteria was irRC. PFS is reported by tumor type. |
From start of treatment to first documented progression or death due to any cause, assessed up to 2.6 years
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CLAG525X2101C
- 2015-000449-21 (EudraCT 번호)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
고급 고형 종양에 대한 임상 시험
-
Töölö HospitalTurku University Hospital; Tampere University Hospital; Jyväskylä Central Hospital; Kymenlaakso...모병
-
Advanced Bionics완전한심한 청력 손실 | Advanced Bionics HiResolution™ Bionic Ear System의 성인 사용자미국
-
University of AlbertaArthritis Society Canada; Wrist Evaluation Canada (WECAN)모병관절염 | 관절 질환 | 근골격계 질환 | 외상 후; 관절염 | 손목 관절염 | 주상골 불유합 | Scapholunate Advanced Collapse | 손목 관절병증캐나다
-
Extremity Medical모병골관절염 | 염증성 관절염 | 손목 터널 증후군(CTS) | 외상 후 관절염 | SLAC(Scapholunate Advanced Collapse) | Scapholunate Crystalline Advanced Collapse(SCAC) | 주상골, 사다리꼴 및 사다리꼴 고급 붕괴(STTAC) | Kienbock의 성인병 | 방사형 부정합 | 척골 전좌 | 주상골 불유합 진행성 허탈(SNAC)미국
-
AstraZeneca모병Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, 위암, 유방암 및 난소암스페인, 미국, 벨기에, 영국, 프랑스, 헝가리, 캐나다, 대한민국, 호주
LAG525에 대한 임상 시험
-
Novartis Pharmaceuticals완전한연조직 육종 | 소세포 폐암 | 위 선암종 | 미만성 대형 B 세포 림프종 | 식도 선암종 | 난소 선암종 | 거세 저항성 전립선 선암종 | 진행된 잘 분화된 신경내분비종양미국
-
Novartis Pharmaceuticals완전한삼중 음성 유방암벨기에, 이탈리아, 일본, 대만, 미국, 호주, 싱가포르, 스페인, 독일, 대한민국, 아르헨티나, 캐나다, 프랑스, 헝가리, 이스라엘, 레바논, 태국
-
Novartis Pharmaceuticals완전한흑색종미국, 이탈리아, 영국, 네덜란드, 캐나다, 독일, 호주, 스페인, 스위스, 프랑스
-
Novartis Pharmaceuticals종료됨삼중 음성 유방암(TNBC)네덜란드, 스페인, 홍콩, 싱가포르, 이탈리아, 호주, 이스라엘, 일본, 미국